Literature DB >> 8228260

Clonal predominance of T cell receptors within the CD8+ CD45RO+ subset in normal human subjects.

R Hingorani1, I H Choi, P Akolkar, B Gulwani-Akolkar, R Pergolizzi, J Silver, P K Gregersen.   

Abstract

Structural models for the TCR alpha/beta predict that the CDR1, CDR2, and CDR3 loops of both the alpha- and beta-chains contribute to specific interactions with the Ag/MHC complex. The CDR3 loops are constructed by joining events involving the V-(D)-J segments, and thus may vary in both sequence and length. We have developed a polymerase chain reaction assay to assess the length variation of the CDR3 loop in TCR derived from seven V beta segment families (V beta 2, V beta 3, V beta 4, V beta 9, V beta 14, V beta 16, and V beta 17). Peripheral blood T cells from 10 normal adults as well as five cord blood samples were studied. CD4+ and CD8+ T cells were analyzed separately. We observed extreme predominance of particular CDR3 lengths in half of the normal adults. These TCR were shown to be clonal by direct sequence analysis. This clonal dominance was found in the CD8+, CD45RO+ T cell population, and was observed in various V segment families. These patterns of TCR clonality were persistent over many months of observation in some individuals. In one subject, the new appearance of a predominant clone was associated with a booster vaccination for hepatitis B. These studies reveal a surprising degree of oligoclonality in the CD8+ cells of normal subjects which may be due to both environmental and genetic factors; the functional significance of persistent clonal dominance in the CD8 compartment remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228260

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  The T cell receptor repertoire of CD8+CD28- T lymphocytes is dominated by expanded clones that persist over time.

Authors:  E N Mugnaini; T Egeland; A Spurkland; J E Brinchmann
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 2.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease.

Authors:  M Lima; J Almeida; A H Santos; M dos Anjos Teixeira; M C Alguero; M L Queirós; A Balanzategui; B Justiça; M Gonzalez; J F San Miguel; A Orfão
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Human CD8 T cells of the peripheral blood contain a low CD8 expressing cytotoxic/effector subpopulation.

Authors:  Axel Trautmann; Beate Rückert; Peter Schmid-Grendelmeier; Eva Niederer; Eva-B Bröcker; Kurt Blaser; Cezmi A Akdis
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

5.  T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1.

Authors:  Weici Zhang; Yoko Ono; Yoshinori Miyamura; Christopher L Bowlus; M Eric Gershwin; Emanual Maverakis
Journal:  J Autoimmun       Date:  2011-06-01       Impact factor: 7.094

6.  Nonmalignant clonal expansions of memory CD8+ T cells that arise with age vary in their capacity to mount recall responses to infection.

Authors:  Jacob E Kohlmeier; Lisa M Connor; Alan D Roberts; Tres Cookenham; Kyle Martin; David L Woodland
Journal:  J Immunol       Date:  2010-08-18       Impact factor: 5.422

7.  Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.

Authors:  E J Claret; E P Alyea; E Orsini; C C Pickett; H Collins; Y Wang; D Neuberg; R J Soiffer; J Ritz
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

8.  Dominant clonotypes in the repertoire of peripheral CD4+ T cells in rheumatoid arthritis.

Authors:  J J Goronzy; P Bartz-Bazzanella; W Hu; M C Jendro; D R Walser-Kuntz; C M Weyand
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

10.  Replacement of the DR alpha chain with the E alpha chain enhances presentation of Mycoplasma arthritidis superantigen by the human class II DR molecule.

Authors:  T Sawada; R Pergolizzi; K Ito; J Silver; C Atkin; B C Cole; M D Chang
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.